Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $558.41 million. The enterprise value is $208.56 million.
| Market Cap | 558.41M |
| Enterprise Value | 208.56M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, before market open.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 139.95 million shares outstanding. The number of shares has increased by 28.89% in one year.
| Shares Outstanding | 139.95M |
| Shares Change (YoY) | +28.89% |
| Shares Change (QoQ) | -2.57% |
| Owned by Insiders (%) | 4.99% |
| Owned by Institutions (%) | 56.33% |
| Float | 125.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| Forward PS | 0.63 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70
| Current Ratio | 0.70 |
| Quick Ratio | 0.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -32.60% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $637,528 |
| Profits Per Employee | -$353,248 |
| Employee Count | 1,543 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 8.77 |
Taxes
In the past 12 months, Novavax has paid $2.03 million in taxes.
| Income Tax | 2.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.82% in the last 52 weeks. The beta is 1.60, so Novavax's price volatility has been higher than the market average.
| Beta (1Y) | 1.60 |
| 52-Week Price Change | -57.82% |
| 50-Day Moving Average | 4.68 |
| 200-Day Moving Average | 6.16 |
| Relative Strength Index (RSI) | 32.06 |
| Average Volume (30 Days) | 7,566,738 |
Short Selling Information
The latest short interest is 43.91 million, so 31.37% of the outstanding shares have been sold short.
| Short Interest | 43.91M |
| Short Previous Month | 48.13M |
| Short % of Shares Out | 31.37% |
| Short % of Float | 35.07% |
| Short Ratio (days to cover) | 5.45 |
Income Statement
In the last 12 months, Novavax had revenue of $983.71 million and -$545.06 million in losses. Loss per share was -$5.41.
| Revenue | 983.71M |
| Gross Profit | 639.94M |
| Operating Income | -566.51M |
| Pretax Income | -543.03M |
| Net Income | -545.06M |
| EBITDA | -487.39M |
| EBIT | -528.62M |
| Loss Per Share | -$5.41 |
Balance Sheet
The company has $578.93 million in cash and $229.08 million in debt, giving a net cash position of $349.85 million or $2.50 per share.
| Cash & Cash Equivalents | 578.93M |
| Total Debt | 229.08M |
| Net Cash | 349.85M |
| Net Cash Per Share | $2.50 |
| Equity / Book Value | -716.93M |
| Book Value Per Share | -5.12 |
| Working Capital | -491.25M |
Cash Flow
In the last 12 months, operating cash flow was -$713.97 million and capital expenditures -$58.81 million, giving a free cash flow of -$772.77 million.
| Operating Cash Flow | -713.97M |
| Capital Expenditures | -58.81M |
| Free Cash Flow | -772.77M |
| FCF Per Share | -$7.67 |
Margins
Gross margin is 65.05%, with operating and profit margins of -57.59% and -55.41%.
| Gross Margin | 65.05% |
| Operating Margin | -57.59% |
| Pretax Margin | -55.20% |
| Profit Margin | -55.41% |
| EBITDA Margin | -49.55% |
| EBIT Margin | -53.74% |
| FCF Margin | -78.56% |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.89% |
| Shareholder Yield | -28.89% |
| Earnings Yield | -97.61% |
| FCF Yield | -138.39% |
Analyst Forecast
The average price target for Novavax is $17.00, which is 326.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 326.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 7.07% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -4.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.37 |
| Piotroski F-Score | 2 |